Preimplantation Genetic Diagnosis is offering to help those that aren't sure if they can have children of their own or if they will suffer from certain medical issues in the future. Pregnancy and Fertility are two other reasons why this test can be offered. The procedure is done when the couple is preparing for conception by checking for any irregularities on an ultrasound. The genetic information from the unaffected parents and the affected eggs are compared to determine if a genetic problem exists with the egg of one of the partners.
The growing number of fertility clinics around the globe coupled with the advancement in the field of genetic analysis is driving the growth of preimplantation genetic diagnosis market. The increasing need for early detection of chromosomal abnormalities in the fetus is another major factor fueling the growth of preimplantation genetic diagnosis market. The advent of next-generation sequencing (NGS) is also contributing to the market growth. Furthermore, the growing prevalence of gene-related disorders is further anticipated to augment the market growth of preimplantation genetic diagnosis . Additionally, growing awareness regarding genetic testing of a specific gene mutation among healthcare workers is again anticipated to foster market growth. Also, increasing maternal age and growing incidence of aneuploidy is expected to uplift the market growth in the near future.
From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to the high incidence of the gene-related disorder in the region. According to the U.S. Department of Health and Human Services, about 1 in 200,000 people in the United States are born with syndrome A each year. Around 1 in 100,000 people in the United States have syndrome A at the present time.
Key Developments:
1. In October 2019, PerkinElmer, Inc., a global provider of innovating for a healthier world, introduced it's PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Diagnosis for Aneuploidy (PGT-A) kit. This solution tests spent embryo culture media for chromosomal abnormalities during in vitro fertilization (IVF) treatment.
2. In October 2018, Vitrolife AB (publ) has entered into a License and Commercialisation Agreement with Illumina, Inc., which provides Vitrolife with exclusive distribution, development, and commercialization rights to Illumina’s preimplantation genetic testing business for IVF in EMEA and Americas.
3. In July 2020, Chromosome Medicina Genômica, powered by GeneOne, enter into a partnership with Genomic Prediction and Diagnostics da America (DASA), to introduce LifeView™ PGT-P to Brazil.
No comments:
Post a Comment